louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04767958: The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing
Official title: The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing to Optimize Patient Care, Resource Allocation and Safety for Frontline Staff
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Covid19
Lead sponsor: Ottawa Heart Institute Research Corporation
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: This is a cohort study of participants falling into one of four groups.
Primary purpose: DIAGNOSTIC

Brief summary: This study is being conducted to study the use and application of a point-of-care (POC) Covid-19 test developed by Spartan BioSciences and recently approved for clinical use by Health Canada.

Detailed description: This RAPID COVID-19 study is a prospective, unblinded clinical trial. POC testing utilizing the Spartan Cube COVID-19 platform will be performed on a cohort of 2200 hospitalized patients who have been tested for COVID-19.

This cohort will be divided into three groups:

1. patients consulted upon by ICU, internal medicine, or cardiology for admission to the hospital
2. patients undergoing cardiac testing and/or procedures
3. patients awaiting surgery The results from the POC test will be compared to the results from the traditional hospital core lab test to determine sensitivity and specificity of the POC test.

An additional cohort of 500 quarantined health care workers will have the POC test performed and compared with the results from the traditional hospital core lab test.

Eligibility criteria: Inclusion Criteria:

* participants \>/= 18 years of age
* patients for whom POC testing would change their course of treatment (in opinion of treatment team)

Exclusion Criteria:

* patients in whom conventional COVID-19 testing would not have otherwise been performed
* patients in whom immediate COVID-19 testing would not alter short-term treatment
* patients who refuse consent

Primary outcomes:
measure: Sensitivity of POC testing as compared to core lab testing
timeFrame: 3 months
Secondary outcomes:
measure: Incidence in which decision making would have been altered by POC testing
timeFrame: 12 months
Other outcomes:
measure: In hospital outcomes
timeFrame: 16 months
measure: Length of hospital admission
timeFrame: 16 months
Locations:
city: Ottawa
country: Canada
facility: University of Ottawa Heart Institute
state: Ontario
Study officials:
References:
Clinical trial NCT00520858: Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women
Official title: Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Obesity
Lead sponsor: Queen's University
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2007-08-27
Enrollment: 145
Sex: ALL
Minimum age (years): 65
Maximum age (years): 80
Standard ages: OLDER_ADULT
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The prevalence of abdominal obesity in the elderly is increasing at alarming rates and thus, requires immediate attention. By comparison to younger adults, obesity reduction in the elderly presents a unique challenge and requires an innovative approach. We propose a novel approach to investigate the effects of different exercise types as independent treatment strategies for the reduction of obesity and related health risk factors in older men and women. We propose that exercise without caloric restriction will be associated with modest weight loss (3-5%), that in turn will be associated with significant reduction in abdominal obesity, insulin resistance, and a corresponding increase in skeletal muscle mass and function. We will determine the separate effects of resistance and aerobic exercise on these primary outcome variables, and, whether a treatment strategy that combines the two is optimal.


Eligibility criteria: Inclusion Criteria:

* Men and women between 65 and 80 years of age.
* Men and women are self-sufficient, sedentary, abdominally obese (BMI between 27 and 34.9 kg/m2; waist circumference greater than 88 cm in women and 102 cm in men), weight stable (± 2 kg) for 6 months prior to the beginning of the study, be non-smokers, and not diabetic.
* We will study elderly women who are not taking hormone replacement therapy to create a homogeneous population in whom the effect of exercise on the principal outcome variables can be evaluated with minimal confounding.

Exclusion Criteria:

* Smokers and diabetics.
* Women taking hormone replacement therapy.

Primary outcomes:
measure: Abdominal obesity
timeFrame: 6 months
Secondary outcomes:
measure: Insulin Resistance
timeFrame: 6 Months
Other outcomes:
Locations:
city: Kingston
country: Canada
facility: Queen's University
state: Ontario
Study officials:
affiliation: Queen's University
name: Robert Ross
role: PRINCIPAL_INVESTIGATOR
References:
citation: Davidson LE, Hudson R, Kilpatrick K, Kuk JL, McMillan K, Janiszewski PM, Lee S, Lam M, Ross R. Effects of exercise modality on insulin resistance and functional limitation in older adults: a randomized controlled trial. Arch Intern Med. 2009 Jan 26;169(2):122-31. doi: 10.1001/archinternmed.2008.558.
Clinical trial NCT00314158: A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open-angle Glaucoma
Ocular Hypertension
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-04-13
Enrollment: 523
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Diagnosis of open-angle glaucoma
* Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

* Under 18
* Pregnant
* Other protocol-defined exclusion criteria may apply

Primary outcomes:
measure: Mean intra-ocular pressure (IOP)
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: United States Investigative Sites
state: Texas
Study officials:
References:
citation: Kaback M, Scoper SV, Arzeno G, James JE, Hua SY, Salem C, Dickerson JE, Landry TA, Bergamini MV; Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008 Oct;115(10):1728-34, 1734.e1-2. doi: 10.1016/j.ophtha.2008.04.011. Epub 2008 Jun 5.
Clinical trial NCT00433758: Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device
Official title: Evaluation of the Performance and Use of the GlucoTrack(TM), Non-Invasive Glucose Monitoring Device
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Gestational Diabetes
Keywords: Diabetes
Blood glucose monitoring
Non invasive Blood glucose monitoring
Lead sponsor: Integrity Applications Ltd.
Sponsor class: INDUSTRY
First posted: 2007-02-12
Enrollment: 142
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to demonstrate the performance of the GlucoTrack device (non invasive device) in measuring blood glucose levels

Detailed description: Diabetes is a leading cause of death in the Western World with medical costs increasing annually. There is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management. Consistently high blood sugar levels can, over time, lead to complications such as blindness, kidney disease, heart disease, and nerve damage.In addition, low blood sugars may lead to immediate dangers. Self-monitoring of blood glucose levels is essential to the self-management of diabetes and has become widespread over the past decade. Blood glucose determinations are currently done by invasive methods (finger tip pricking), followed by measuring the blood drop characteristics. Currently, there is no commercially available reliable non-invasive glucose measurement device that being marketed.

The GlucoTrack, non-invasive device for determining glucose levels based on the simultaneous measurement of three independent orthogonal parameters.

The rationale for development of the device is to improve the patient's quality of life by providing a device that is easily used and provides a painless measurement method, thereby leading to higher compliance, and to better managed diabetes

Eligibility criteria: Inclusion Criteria:

* Patients with Type 1, Type 2, or Gestational Diabetes
* Above the age of 10

Exclusion Criteria:

* Does not meet inclusion criteria
* Patients requiring dialysis
* Participation in other clinical investigations within the previous month.
* Pregnancy(excluding patients that intend to participate in the gestational group)

Primary outcomes:
measure: Clarke Error Grid
timeFrame: Clarke Error Grid
Secondary outcomes:
Other outcomes:
Locations:
city: Beer-Sheva
country: Israel
facility: Soroka University Medical Center
Study officials:
affiliation: Soroka University Medical Center
name: Ilana Harman-Boehm, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06954558: A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
Official title: The Phase I, Open-label, Single-arm Clinical Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of GK01 Cell Injection in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumors
Keywords: efficacy
safety
PK
TILs
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
Collaborators: name: Beijing Geek Gene Technology Co., LTD
First posted: 2025-05-01
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a Phase I, open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.


Eligibility criteria: 1. Ability to understand and sign a written informed consent document；
2. At the date of signing ICF, 18 \~70 years old, male or female；
3. Histopathological confirmed advanced solid tumor patients who have failed to standard treatment or intolerance with standard treatment；
4. There is at least one resectable tumor lesion that has not received radiation therapy or other local therapies;
5. At least one measurable lesion at baseline per RECIST version 1.1；
6. The expected survival time is more than 12 weeks;
7. ECOG 0-1 points;
8. Adequate organ functions

Primary outcomes:
measure: Safety and Tolerability
timeFrame: 2 years
Secondary outcomes:
measure: PK
timeFrame: 2 years
measure: Objective response rate (ORR)
timeFrame: 2 years
measure: Progress-free survival(PFS)
timeFrame: 2 years
measure: Overall survival (OS )
timeFrame: 2 years
measure: Disease control rate (DCR)
timeFrame: 2 years
measure: Patient Quality of Life
timeFrame: 2 years
measure: PD marker
timeFrame: 2 years
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute & Hospital
Study officials:
References:
Clinical trial NCT01779258: Emollients in the Management of Atopic Dermatitis
Official title: Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atopic Dermatitis
Keywords: xerosis
dry skin
dermatitis
eczema
emollient
corticosteroid
flare
Lead sponsor: Pierre Fabre Medicament
Sponsor class: INDUSTRY
First posted: 2013-01-30
Enrollment: 347
Sex: ALL
Minimum age (years): 2
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to confirm that emollients play a major role in the maintenance therapy after clearing of inflammatory lesions and can reduce occurrence of flares in children with atopic dermatitis.


Eligibility criteria: Inclusion Criteria:

* Age between 2 and 6 years included,
* Presenting with atopic dermatitis, with at least one duly documented flare treated by corticosteroids within the previous 6 months, and presenting a current flare (objective Scoring for Atopic Dermatitis (SCORAD score) is \[15-40\] at inclusion),
* After treatment of the current flare, patients should have for randomization an Objective SCORAD score \< 15, with Xerosis intensity≥ 1 and no subjective signs

Exclusion Criteria:

* Severe form of atopic dermatitis requiring either systemic corticosteroid treatment and/or antibiotic or antiviral treatment and/or hospitalisation,
* Primary bacterial, viral, fungal or parasitic skin infection,
* Ulcerated lesions, acne or rosacea,
* Dermatological disease other than atopic dermatitis which could interfere with the assessment,
* Immunosuppression,

Primary outcomes:
measure: Percentage of patients with at least one flare over the treatment period
timeFrame: 12 weeks of treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Tallinn
country: Estonia
city: Tartu
country: Estonia
city: Bordeaux
country: France
city: Poitiers
country: France
city: Vilnius
country: Lithuania
city: Pruszków
country: Poland
city: Płock
country: Poland
city: Warszawa
country: Poland
city: Łódź
country: Poland
city: Braşov
country: Romania
city: Bucharest
country: Romania
city: Craiova
country: Romania
city: Iaşi
country: Romania
city: Sibiu
country: Romania
city: Targu Mureş
country: Romania
Study officials:
References:
Clinical trial NCT03120858: Turkish Version of the Kinesthetic and Visual Imagery Questionnaire
Official title: Reliability and Validity of the Turkish Version of the Kinesthetic and Visual Imagery Questionnaire
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Image, Body
Healthy
Pain
Keywords: motor imagery
kinesthetic imagery
reliability
Turkish version
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2017-04-19
Enrollment: 185
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: Imagery is determined with two strategies to mentally simulate the movements: visual and kinesthetic imagery. Visual motor imagery (VMI) is associated with spatial coordinates of a movement in the environment and through this speciality VMI applies mainly to the imagery of moving objects or to movement of another person in the imagined environment, although imagine of own movement is also possible. Kinesthetic motor imagery depends on dynamic relationship among the individual, the movement and the environment and it should be determined by the nature of the task, the environment and individual characteristics and also requires "feel" the movement.

The aim of this study is to translate this questionnaire into Turkish and the translation in terms of its internal consistency, test-retest reliability.


Eligibility criteria: Inclusion Criteria:

* ages between 18-65 years, healthy volunteers, with no limitation in mobility or movement disorder, with no chronic pain

Exclusion Criteria:

* refuse to attend to the study, neurological conditions

Primary outcomes:
measure: Cronbach's Alpha coefficient
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
Study officials:
References:
Clinical trial NCT05341258: Arterial and End-Tidal CO2 Gradient as a Mortality Predictor in Critical Care Patients
Official title: Arterial and End-Tidal CO2 Gradient as a Mortality Predictor in Critical Care Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Critical Illness
Ventilation Perfusion Mismatch
Shock
Pulmonary Embolism
Trauma
Copd
Lead sponsor: Gaziosmanpasa Research and Education Hospital
Sponsor class: OTHER_GOV
First posted: 2022-04-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Scoring systems (SOFA, APACHE-II etc.) are used to estimate the mortality rates of patients treated in the intensive care unit. . In the scoring systems used, the disfunction level of the organs of the patients is measured. Blood gas analysis is routinely performed in patients whom intubated in the intensive care unit and receiving mechanical ventilation support, and the patient's treatment is optimized according to the results of the examination. The patient's mechanical ventilation settings are regulated by analyzing the Partial Arterial Carbondioxide (paCO2) value in the patient's blood gas result. The difference between the paCO2 value in the blood gas and the End-tidal Carbondioxide (EtCO2) value measured in the mechanical ventilator is 3-5mmHg in normal healthy people, while this difference is seen more in critical care patients. In critically ill patients in the intensive care unit, there is a greater increase in the difference between paCO2 and ETCO2 in cases where mortality is high, such as global perfusion disorder, shock situations, and massive pulmonary embolism, etc. In this study, it was planned to investigate the use of the difference between the paCO2 value in the blood gas taken from the patient and the ETCO2 value measured in the mechanical ventilator to predict the mortality rate of the patient.


Eligibility criteria: Inclusion Criteria:

* Critical Care Patients intubated in last 24 hours.

Exclusion Criteria:

* Patients younger than 18 years old.

Primary outcomes:
measure: Mortality
timeFrame: 6 months
Secondary outcomes:
measure: ICU Length of Stay
timeFrame: 6 months
measure: Ventilator Free Days
timeFrame: 6 months
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Gaziosmanpasa Training Research Hospital
Study officials:
affiliation: Director of Anesthesiology and Reanimation Department
name: Ulku Aygen Turkmen, Proffessor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01272258: A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Observed Systemic, Long-Acting, Anti-HIV Treatment With a Monoclonal Anti CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-Infected Injection Drug Users With Viral Rebound and Documented Poor Adherence to the Previous Antiretroviral Regimen
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: HIV
Lead sponsor: CytoDyn, Inc.
Sponsor class: INDUSTRY
First posted: 2011-01-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an adjunct to a new, optimized, oral antiretroviral regimen in HIV-infected injection drug users with viral rebound and documented poor adherence to the previous antiretroviral regimen.


Eligibility criteria: Key Inclusion Criteria:

1. Only R5 virus
2. HIV-1 RNA \> 1,000 copies/mL but \< 100,000 copies/mL
3. CD4+ lymphocyte counts \> 100 cells/μL
4. Non-prescription recreational drug use within the previous 6 months

Key Exclusion Criteria:

1. Females who are pregnant (positive blood test), lactating, or breastfeeding, or who plan to become pregnant during the study
2. Prior use of any CCR5 entry inhibitors
3. History of any acquired immune deficiency syndrome (AIDS)-defining illness

Primary outcomes:
measure: Specific measure that will be used to determine the effect of the interventions: Percentage of subjects without virologic failure at week 24.
timeFrame: 24 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Drexel University College of Medicine
state: Pennsylvania
Study officials:
References: